

IMPACT OF USING ADJUSTED IDEAL WEIGHT FOR CARBOPLATIN DOSING IN OVERWEIGHT ONCOLOGY PATIENTS: A RETROSPECTIVE ANALYSIS



Castejón Grao I, García Zafra V, Carreño Dato I, Jiménez Pulido IP, Matoses Chirivella C, Murcia López AC.



Hospital General Universitario de Elche, Pharmacy Department (farmaelx@gva.es)



BACKGROUND AND IMPORTANCE



AIM AND OBJECTIVES

Retrospectively analyse carboplatin dosing in cancer patients to determine whether overweight patients were overdosed by comparing actual weight prescribed dose ($_{AR}$ dose) and AIW calculated dose ($_{AIW}$ dose). In addition, study the possible relationship between overdose and toxicity onset.



MATERIAL AND METHODS



DATA COLLECTED		
From Farmis-oncofarm® and Orion Clinic®		
sex	age	weight
height	Cr	AUC
body mass index (BMI)	$_{AR}$ dose in cycle 1	% of prescribed dose

ANALYSIS

- $_{AIW}$ dose = AIW + same values for the variables
- $[(_{AR}dose - _{AIW}dose) / _{AIW}dose] \times 100$ = Variation between $_{AR}$ dose and $_{AIW}$ dose in overweight patients; positive value = overdose

TOXICITY

If dose reduction due to toxicity → studied relationship with overweight

RESULTS

38 PATIENTS


Description	Carboplatin dosage
median of 65 (18) years	mean $_{AR}$ dose in the first cycle was 564.7 (116.7) mg
24 (63.2%) women	
mean weight 73.5 (12.6) kg	with Cr 0.8 (0.2) mg/dL
mean height 161.3 (7.9) cm	
29 (76.3%) patients were overweight (BMI ≥ 25)	AUC used: 4 (5.3%), 5 (84.2%), 6 (10.5%)

29 OVERWEIGHT PATIENTS

mean $_{AR}$ dose was 567.0 (123.8) mg
 mean $_{AIW}$ dose 501.8 (118.4) mg
 mean variation 13.7 (8.8) %.

16/38 (42.1%) WITH DOSE REDUCTION due to

1/16 (6.3%) worsening Cr 6/16 (37.5%) weight change 7/16 (43.8%) toxicity 2/16 (12.5%) the latter two factors



9 out of 38 patients with toxicity → 7/9 (77.8%) were patients with a BMI ≥ 25

7 out of 29 overweight patients had toxicity → 7/29 (24,1%)

CONCLUSION AND RELEVANCE

In the population studied, the difference between $_{AR}$ dose and $_{AIW}$ dose indicates overdose in overweight patients. Most carboplatin-related toxicity cases occurred in these patients. These findings suggest that using AIW for dosing may reduce toxicity risk and warrant prospective confirmation.

5PSQ-122



ACKNOWLEDGEMENTS: Thanks to my service for your unconditional support.